12/19/2012

Avaxia Biologics secured $6.4 million in a Series B funding round from new and existing investors. The firm will use the proceeds to fund an early-stage trial of AVX-470, an anti-TNF antibody, in patients with ulcerative colitis and Crohn's disease.

Related Summaries